Interventions targeted at mitigating the risk of preeclampsia may reduce preterm birth and cesarean delivery in women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis. That’s one key finding of a retrospective study published in Arthritis Care & Research.1 The study set out to quantify the mediated effects of autoimmune conditions on adverse…
Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.
We have all been there when a patient with a systemic autoimmune disease needs sudden coordination of care. Your patient with Behçet’s disease nonchalantly mentions he hasn’t been able to see out of his right eye for two days. The spouse of one of your patients with sarcoidosis writes to you on the patient portal…
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown…
EULAR 2020 e-CONGRESS—In what speakers at the European e-Congress of Rheumatology described as the first treat-to-target and tight control (T2T/TC) strategy trial in axial spondyloarthritis (AxSpA), researchers found such a strategy has both health and financial benefits. In the year-long study—called TICOSPA—centers were randomized to apply either a T2T/TC strategy or care left to the…
Here’s a taste of what participants in this year’s virtual annual meeting, ACR Convergence 2020, will have access to during Down & Dirty 30, four 30-minute sessions designed to provide refreshers on specific rheumatology-related topics.
Advancements in technology and artificial intelligence designed to aid rheumatologists in diagnosing patients and predicting mortality risk were discussed in depth during a session of the European e-Congress of Rheumatology.
During the 2020 ACR State-of-the-Art Clinical Symposium, Zoltán Szekanecz, MD, PhD, addressed the risks of vascular disease and how to manage them in patients with rheumatic diseases.
Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…
In June, the FDA approved secukinumab to treat non-radiographic axial spondyloarthritis after data from a clinical trial demonstrated its efficacy…